Switching the microglial harmful phenotype promotes lifelong restoration of Subtantia Nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice

Rejuvenation Research

Volumn 14, Issue 4, 2011, Pages 411-424

  L'Episcopo, Francesca ^a   Tirolo, Cataldo ^a   Testa, Nunzio ^a   Caniglia, Salvatore ^a   Morale, Maria Concetta ^a   Impagnatiello, Francesco ^b   Marchetti, Bianca ^a,c,d  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b Nicox Research Institute   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLURBIPROFEN 4 NITROXYBUTYL ESTER; LIPOPOLYSACCHARIDE; NITRIC OXIDE;

ARTICLE; CELL ACTIVATION; DOPAMINERGIC NERVE CELL; IMMUNOMODULATION; LIFESPAN; MICROGLIA; NERVE CELL; NERVE DEGENERATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGING; ANIMALS; DOPAMINERGIC NEURONS; FLURBIPROFEN; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NERVE DEGENERATION; NERVE REGENERATION; NITROSATION; OXIDATIVE STRESS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 80051993172     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2010.1134     Document Type: Article

References (72)

1. Olanow CW, Shapira AHV, Agid Y. Neurodegeneration and prospects for neuroprotection and rescue in Parkinson's disease. Annal Neurol 2003;53(Suppl 3):S26-S38.
2. Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010;39:156-161.
3. Langston JW, Forno LS, Tetrud J, Reevers AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46: 598-605. (Pubitemid 29466438)
4. Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003; 53:S16-S25. (Pubitemid 36368559)
5. Boger HA, Granholm AC, McGinty JF, Middaugh LD. A dual-hit animal model for age-related parkinsonism. Prog in Neurobiol 2010;90:217-229.
6. McGeer PL, Itagaki S, Boyes BE, McGeer, EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
7. Chen H, Jacobs EJ, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963-967. (Pubitemid 41746889)
8. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 2009;8: 382-397.
9. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008;29:357-365.
10. Przedborski S. Inflammation and Parkinson's disease pathogenesis. Mov Disord 2010;25:S55-S57.
11. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 2010;9:349-372.
12. Morale MC, L'Episcopo F, Tirolo C, Giaquinta G, Caniglia S, Testa N, Arcieri P, Serra, PA, Lupo G, Alberghina M, Harada N, Honda S, Panzica GC, Marchetti B. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev 2008;57:431-443.
13. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2004;24:395-401.
14. Marchetti B, Kettenmann H, Streit WJ. Glia-Neuron Crosstalk in Neuroinflammation, Neurodegeneration and Neuroprotection. Brain Res. Review Special Issue 2005;482: 129-489.
15. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit J Pharmacol 2007;150:963-976. (Pubitemid 46628616)
16. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510-518.
17. McGeer P, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008;23:474-83.
18. Marchetti B, Abbracchio MP. To be or not to be (inflammed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases? Trends Pharmacological Sci 2005;26:517-525. (Pubitemid 41338562)
19. Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: Glia as a common final pathway. Ann NY Acad. Sci 2005;1057:296-318. (Pubitemid 43211642)
20. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005;25:9275-9284. (Pubitemid 41500836)
21. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008;131:1880-1894.
22. Liberatore GT, Jacksons-Lewis V, Vukosavic C, Mandir AS, Vila M, McAuliffe WG. Inducibile nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-1409.
23. Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001;21:6480-6491. (Pubitemid 32781092)
24. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-a in the subtantia nigra elicits progressive neurodegneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis 2010;37:630-640.
25. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem 2002;81:1285-1297.
26. Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L'Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: Critical role of glial nitric oxide. FASEB J 2004;18:164-166.
27. Qin L, Liu Y, Wang T, Wie SJ, Blocl ML, Wilson B. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004;279:1415-1421. (Pubitemid 38082669)
28. Mander P, Brown G. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: A dual key mechanism of inflammatory degeneration. J Neuroinflamm 2005;2:20-27.
29. Marchetti B, Serra PA, Tirolo C, L'Episcopo F, Caniglia S, Gennuso F, Testa N, Miele E, Desole MS, Barden N, Morale MC. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental Parkinsonism: Pivotal role for glia-neuron interactions. Brain Res Rev 2005;48: 302-321. (Pubitemid 40585761)
30. Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B. Microglial PHOX and Mac-1 essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007;55:1178-1188. (Pubitemid 47204209)
31. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 2008;181: 7194-7204.
32. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-5478. (Pubitemid 36542729)
33. Kurkowska-Jjastrezba I., Członkowski A., Członkowska A. Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol 2006;59:988-989.
34. Vijitruth R, Liu M, Choi DY, Nguyen XB, Hunter RL, Bing G. Ciclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model Parkinson's disease. J Neuroinflammation 2006;3:6.
35. Hunter RL, Dragivecic N, Seifert K, Choi DY, Liu M, Kim HC, Cass, WA, Sullivan PG, Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007;100: 1375-1386.
36. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurology 2007;205:295-312. (Pubitemid 46778915)
37. Asanuma M, Miyazaki I. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurology 2007;206:172-178. (Pubitemid 47094768)
38. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005;2:355-365. (Pubitemid 40980194)
39. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s-110s.
40. Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition and cardiovascular risk. Trends Pharmacol. Sci 2009;30:503-508.
41. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: Possible neurochemical mechanisms. Adv Neurol1993;60.
42. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, Johnson RW. Exaggerated neuroinflammation and sickness behaviour in aged mice after activation of the peripheral innate immune system. FASEB J 2005;19:1329-1331. (Pubitemid 41113739)
43. Henry CJ, Huang Y, Wynne A, Godbout JP. Peripheral Lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1b and antiinflammatory IL-10 cytokines. Brain Behav Immun 2009;23: 309-317.
44. Flanary B. The role of microglial cellular senescence in the aging and Alzheimer diseased brain. Rejuvenation Res 2005;8:82-85. (Pubitemid 40840501)
45. Streit WJ. Microglial senescence: Does the brain's immune system have an expiration date? Trends Neurosci 2006;29: 506-510. (Pubitemid 44291814)
46. Flanary NW, Sammons C, Nguyen C, Walker D, Streit WJ. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res 2007;10:61-74.
47. Njiea MG, Boelenb E, Stassenb FR, Steinbusch HWM, Borchelta DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging 2010;Jun 25. [Epub ahead of print]
48. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009;118:475-485.
49. Damani MR, Zhao L, Fontainhas AM, Amaral J, Fariss RN. Age-related alterations in the dynamic behavior of microglia. Aging Cell 2011;10:263-276.
50. Dringen R. Oxidative and antioxidative potential of brain microglial cells: Antioxid, Redox Signal 2005;7:1223-1233. (Pubitemid 41232519)
51. Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: Mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008;22:453-464.
52. Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J Biol Chem 2004;279:51647-51653. (Pubitemid 40017915)
53. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000;7:429-447.
54. Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 2005; 22:317-30. (Pubitemid 41097605)
55. Ling ZD, Chang Q, Lipton JW, Tong CW, Carvwy PM. Rotenone potentiates dopamine neuron loss in animal exposed to lipopolysaccharide prenatally. Exp Neurol 2004; 190:373-383.
56. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1b increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation 2008;5:8.
57. Qin L,Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. Systemic LPS causes chronic neuroinflammation and pregressive neurodegeneration. Glia 2007;55:453-462. (Pubitemid 46383175)
58. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002;137:295-340.
59. Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, Gasparini L, Butti E, Comi G, Ongini E, Martino G. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004;150:10-19. (Pubitemid 38481643)
60. Fiorucci S, Antonelli E. NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 2006;5:121-131. (Pubitemid 43796674)
61. L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroinflammation 2010;7:83-104.
62. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318. (Pubitemid 26349059)
63. Anuar F, Whiteman M, Siau JL, Kwong SE, Bhatia M, Moore PK. Nitric oxide-releasing flurbiprofen reduces formation of proinflammatory hydrogen sulfide in lipopolysaccharidetreated rat. Br J Pharmacol 2006;147:966-974
64. Gennuso F, Fernetti C, Tirolo C, Testa N, L'Episcopo F, Caniglia S, Morale MC, Ostrow JD, Pascolo L, Tiribelli C, Marchetti B. Bilirubin protects astrocytes from its own toxicity inducing up-regulation and translocation of multigrug resistance-associated protein 1 (Mrp 1). Proc Natl Acad Sci USA 2004;101:2470-2475. (Pubitemid 38269335)
65. Marchetti B, Morale MC, Brouwer J, Tirolo C, Testa N, Caniglia S, Barden N, Amor S, Smith PA, Dijkstra CD. Exposure to a dysfunctional glucocorticoid receptor from early embryonic life programs the resistance to experimental autoimmune encephalomyelitis via nitric oxide-induced immunosuppression. J Immunol 2002;168:5848-5859. (Pubitemid 34556173)
66. Gallo F, Morale MC, Spina-Purrello V, Tirolo C, Testa N, Farinella Z, Avola R, Beaudet A, Marchetti B. Basic fibroblast growth factor (bFGF) acts on both neurons and glia to mediate the neurotrophic effects of astrocytes on LHRH neurons in culture, Synapse 2000;36:233-253. (Pubitemid 30257309)
67. Wenk GL, Rosi S, McGann K, Hauss-Wegrzyniak B. A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Eur J Pharmacol 2002;453:319-324 (Pubitemid 35223525)
68. Gasparini L, Ongini E, Wilcock D, Morgan D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev 2005;48:400-408. (Pubitemid 40585770)
69. Herman AG, Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 2005;26:1945-1955. (Pubitemid 41435726)
70. Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdellatif KR, Keefer LK, Kashfi K. Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs. J Pharmacol Exp Ther 2010;335:443-450.
71. Idris Al, Ralston SH, van't Hof RJ. The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur J Pharmacol 2009;602:215-222.
72. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, D'Adamo P, Zardini E, Andreoni L, Ihkwaba AEC, Serra PA, Franciotta D, Martino G, Pluchino S, Marchetti B. Reactive astrocytes and Wnt/b-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011;41:508-527.